Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

Blood

Volumn 120, Issue 10, 2012, Pages 2098-2108

  Gallagher, Robert E ^a,b   Moser, Barry K ^c   Racevskis, Janis ^b   Poiré, Xavier ^d   Bloomfield, Clara D ^e   Carroll, Andrew J ^f   Ketterling, Rhett P ^g   Roulston, Diane ^h   Schachter Tokarz, Esther ^b   Zhou, Da Cheng ^b   Chen, I Ming L ⁱ   Harvey, Richard ⁱ   Koval, Greg ^j   Sher, Dorie A ^j   Feusner, James H ^k   Tallman, Martin S ^l   Larson, Richard A ^j   Powell, Bayard L ^m   Appelbaum, Frederick R ⁿ   Paietta, Elisabeth ^a,b   Willman, Cheryl L ⁱ   Stock, Wendy ^j   more..

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY   (United States)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g Mayo Clinic   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ UNIVERSITY OF NEW MEXICO   (United States)

^j UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^k CHILDREN S HOSPITAL OAKLAND   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m WAKE FOREST BAPTIST HEALTH   (United States)

ⁿ UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHILD; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; INTERNAL TANDEM DUPLICATION MUTATION; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LIGAND BINDING; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DOMAIN; SCHOOL CHILD;

EID: 84866156989     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-407601     Document Type: Article

References (45)

1. Kogan SC. Mouse models of acute promyelocytic leukemia. Curr Top Microbiol Immunol. 2007;313:3-29.
2. Grimwade D, Biondi A, Mozziconacci MJ, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood. 2000;96(4):1297-1308.
3. Gallagher RE, Willman CL, Slack JL, et al. Association of PML-RARalpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997;90(4):1656-1663.
4. Beitinjaneh A, Jang S, Roukoz H, Majhail NS. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010;34(7):831-836.
5. Le Beau MM, Bitts S, Davis EM, Kogan SC. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood. 2002;99(8):2985-2991.
6. Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 2009;15(13):4263-4269.
7. Le Beau MM, Davis EM, Patel B, Phan VT, Sohal J, Kogan SC. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia. Blood. 2003;102(3):1072-1074.
8. Gale RE, Hills R, Pizzey AR, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106(12):3768-3776.
9. Akagi T, Shih LY, Kato M, et al. Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood. 2009;113(8):1741-1748.
10. Cervera J, Montesinos P, Hernandez-Rivas JM, et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010;95(3):424-431.
11. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monotherapy: a multicenter study by the PET-HEMA group. Blood. 2004;103(4):1237-1243.
12. Callens C, Chevret S, Cayuela JM, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19(7):1153-1160.
13. Barragan E, Montesinos P, Camos M, et al. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with alltrans retinoic acid and anthracycline monochemotherapy. Haematologica. 2011;96(10):1470-1477.
14. Schnittger S, Bacher U, Haferlach C, Kern W, Alpermann T, Haferlach T. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t (15;17)/PML-RARA. Haematologica. 2011;96(12):1799-1807.
15. De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801-806.
16. Gallagher RE, Yeap BY, Bi W, et al. Quantitative real-time RT-PCR analysis of PML-RARalpha mRNA in adult acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood. 2003;101(7):2521-2528.
17. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322(5906):1377- 1380.
18. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330):356-361.
19. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(22):1021-1028.
20. Ding W, Li YP, Nobile LM, et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood. 1998;92(4):1172-1183.
21. Gallagher RE, Schachter-Tokarz EL, Zhou D-C, et al. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure. Leukemia. 2006;20(4):556-562.
22. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751-3757.
23. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503-2516.
24. Noguera N, Breccia M, Divona M, et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002;16(11):2185-2189.
25. Moser BK. Statistics for clinicians: P values. Clin Adv Hematol Oncol. 2007;5(4):251-253.
26. Cote S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller WH Jr. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood. 2000;96(9):3200-3208.
27. Zhou D-C, Kim S, Ding W, Schulz C, Warrell RP Jr, Gallagher RE. Frequent mutations in the ligand binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood. 2002;99(4):1356-1363.
28. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia. 2002;16(10):1940-1958.
29. Cote S, Rosenauer A, Bianchini A, et al. Response to histone deacetylase inhibition of novel PML/RARalpha mutant detected in retinoic acid-resistant APL cells. Blood. 2002;100(7):261-270.
30. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94(4):1192-1200.
31. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As203 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101(15):5328-5335.
32. Rego EM, Kim HT, Ruiz-Arguelles GJ, et al. Improving the treatment outcome of acute promyelocytic leukemia in developing countries through an international cooperative network: Report on the International Consortium on Acute Promyelocytic Leukemia Study Group [abstract]. Blood. 2009;114(22):5a. Abstract 6.
33. Westervelt P, Lane AA, Pollock JL, et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood. 2003;102(5):1857-1865.
34. Wojiski S, Guibal FC, Kindler T. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia. 2009;23(8):1462-1471.
35. Kogan SC, Hong SH, Shultz DB, Privalsky ML, Bishop JM. Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood. 2000;95(5):1541-1550.
36. Raghavan M, Smith LL, Lillington DM, et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood. 2008;112(3):814-821.
37. Walter MJ, Park JS, Lau SKM, et al. Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cel Biol. 2004;24(24):10882-10893.
38. Jones L, Wei G, Sevcikova S, et al. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med. 2010;207(12):2581-2594.
39. Wartman LD, Larson DE, Xiang Z, et al. Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J Clin Invest. 2011;121(4):1445-1455.
40. Manola KN, Karakosta M, Sambani C, et al. Iso-chromosome der(17)(q10)t(15;17) in acute promyelocytic leukemia resulting in an additional copy of the RARA-PML fusion gene: report of 4 cases and review of the literature. Acta Haematol. 2010;123(3):162-170.
41. Berger R, Le Coniat M, Derre J, Vecchione D, Jonveaux P. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities. Genes Chromosomes Cancer. 1991;3(5):332-337.
42. Haraguchi K, Ohno N, Tokunaga M, et al. Masked t (15;17) APL with the insertion of PML-RARalpha fusion gene in 4q21. Leuk Res. 2009;33(11):1552-1555.
43. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
44. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2007;20(1):57-65.
45. Schachter-Tokarz E, Kelaidi C, Cassinat B, et al. PML-RARalpha ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL. Leukemia. 2010;24(2):473-476.